Imricor Medical Systems (IMR) H2 2024 earnings summary

Executive summary

• Achieved significant regulatory milestones in 2024, including CE mark approvals for new devices, US FDA modular review progress, and Saudi FDA approval, with first MRI-guided procedures at major hospitals in the US, Switzerland, and Croatia.

• Entered early stages of global commercialization, expanding into Europe, the Middle East, and the US, with new site activations and a growing sales pipeline.

• Focused on expanding applications beyond cardiac ablation, including biopsy tools, renal denervation, and AI integration for broader diagnostic and therapeutic use.

• Revenue is primarily generated from product sales, with additional income from consulting and service contracts.

• The company reported recurring operating losses and negative cash flows for 2024 and 2023, raising substantial doubt about its ability to continue as a going concern.

Financial highlights

• Total revenue for 2024 was $959,424, up 56% year-over-year, driven by higher product and service sales and new site activations.

• Equipment revenue rose 109% to $306,000, and consumable product sales increased 59% to $461,000, with first sales in the Middle East.

• Net loss for the period was $29,692,831, up 31% year-over-year, primarily due to fair value changes in convertible notes and warrants; adjusted net loss was $15,600,000, down 7% from the prior year.

• Operating expenses remained high at $17,256,236 in 2024, with R&D and G&A as major components.

• Cash balance at year-end was $15,707,739 after raising over $30 million in equity and rights offerings.

Outlook and guidance

• Anticipates CE mark approval for Northstar by mid-2025 and FDA clearance in Q3, enabling first US sales and broader hospital adoption.

• Expects major regulatory milestones and new customer site additions in Europe and the Middle East throughout 2025, with acceleration in the second half as Philips software update enables more site activations.

• Visible VT clinical trial and first-in-man MRI-guided VT ablation at Amsterdam University Medical Center are key near-term milestones.

• Management plans to raise additional working capital through equity or debt offerings to sustain operations.

• The company expects to recognize $129,794 in revenue from unsatisfied performance obligations in 2025.